Journal
ONCOTARGET
Volume 8, Issue 18, Pages 29846-29856Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.16165
Keywords
targeted photodynamic therapy; esophageal cancer; epidermal growth factor receptor family (HER-family); targeted treatment
Categories
Funding
- Dutch Cancer Society / Alpe d'HuZes [RUG 2012-5416]
Ask authors/readers for more resources
Esophageal carcinoma (EC) is a global health problem, with disappointing 5-year survival rates of only 15-25%. Near-infrared targeted photodynamic therapy (NIR-tPDT) is a novel strategy in which cancer-targeted phototoxicity is able to selectively treat malignant cells. In this in vitro report we demonstrate the applicability of antibody-based NIR-tPDT in esophageal adenocarcinoma (EAC), using the phototoxic compounds cetuximab-IRDye700DX and trastuzumab-IRDye700DX, targeting respectively epidermal growth factor receptor 1 (EGFR) and 2 (HER2). Furthermore, we demonstrate that NIR-tPDT can be made more effective by tyrosine kinase inhibitor (TKI) induced growth receptor upregulation. Together, these results unveil a novel strategy for non-invasive EAC treatment, and by pretreatment-induced receptor upregulation its future clinical application may be optimized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available